Management of spondyloarthropathies

Current Opinion in Rheumatology

Volumn 8, Issue 4, 1996, Pages 288-295

  Cuellar, Marta Lucia ^a   Espinoza, Luis R ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; METHOTREXATE; SALAZOSULFAPYRIDINE;

ANKYLOSING SPONDYLITIS; ANTIBIOTIC THERAPY; ARTICLE; DRUG EFFICACY; DRUG USE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; PHYSIOTHERAPY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY;

EID: 0029756660     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199607000-00004     Document Type: Article

References (52)

1. Khan MA: Medical and surgical treatment of seronegative spondyloarthropathy. Curr Opin Rheumatol 1990, 2:592-599.
2. Espinoza LR, Zakraoui L, Espinoza CG, Gutierrez F, Jara LJ, Silveira LH, Cuellar ML, Martinez-Osuna P: Psoriatic arthritis: clinical response and side effects of methotrexate therapy. J Rheumatol 1992, 19:872-876.
3. Gladman DD, Schuckett R, Russell ML, Thorne JC, Schachter RK: Psoriatic arthritis (PsA): an analysis of 220 patients. Q J Med 1987, 238:127-141.
4. Lahuio A, Leirisalo-Repo M, Lahdevirta J, Saikku P, Repo H: Double-blind, placebo-controlled study of three month treatment with lymecycline in reactive arthritis, with special reference to chlamydia arthritis. Arthritis Rheum 1991, 34:6-14.
5. Gladman DD, Farewell VT, Nadeau C: Clinical indicators of progression in psoriatic arthritis: multivariate relative risk model. Arthritis Rheum 1995, 22:675-679.
6. Amor B, Dougados M, Khan MA: Management of refractory ankylosing spondylitis and related spondyloarthropathies. Rheum Dis Clin North Am 1995, 21:117-128. This review focuses on the therapeutic management of refractory spondyloarthropathies. It presents a rational approach and simplistic definition of this difficult topic.
7. Amor B, Silva-Santos R, Nahal R, Listrat V, Dougados M: Predictive factors of the long term outcome of spondyloarthropathies. J Rheumatol 1994, 21:1883-1886.
8. Dougados M: Tratamiento médico de las espondiloartropatias [in Spanish]. Rev Esp Reumatol 1995, 22:241-246.
9. Gálvez-Hernàndez JM, Molero A, Pena Arrebola A: Tratamiento rehabilitador de las espondiloartropatias [in Spanish]. Rev Esp Reumatol 1995, 22:247-251. A good overview on rehabilitation and physical therapy modalities.
10. Dougados M, van der Linden S, Leirisalo-Repo M, Huitfeldt B, Juhlin R, Veys E, Zeidler H, Kvien TK, Olivieri, Dijkmans B, et al.: Sulfasalazine in the treatment of spondyloarthropathy. Arthritis Rheum 1995, 5:618-627. A 6-month randomized, multicenter, double-blind, placebo-controlled study found a statistical significant difference in efficacy for sulfasalazine in the patients' overall assessment, erythrocyte sedimentation rate, platelet count, and a strong tendency for improvement in pain and in the physicians' overall assessment, particularly in patients with PsA.
11. Laasila K, Leirisalo-Repo M: Side effects of sulphasalazine in patients with rheumatic diseases or inflammatory bowel disease. Scand J Rheumatol 1994, 23:338-340.
12. Dougados M, Nguyen M, Caporal R, Legeais J, Bouxin-Sauzet A, Pellegri Guegnault B, Gomeni C: Ximoprofen in ankylosing spondylitis: a double blind placebo controlled dose ranging study. Scand J Rheumatol 1994, 23:243-248.
13. Cuvelier C, Mielants H, Quatuker J, De-Vos M, Veys EM, Roels H: Spondyloarthropathy and gut inflammation: immunogenetic mechanisms. Int J Tissue React 1992, 43:172-176.
14. Feltelius N, Hvatum Mete, Brandtzaeg P, Knutson L, Hällgren R: Increased jejunal secretory IgA and IgM in ankylosing spondylitis: normalization after treatment with sulfasalazine. J Rheumatol 1994, 21:2076-2081.
15. Nissilä M, Lahesmaa R, Leirisalo-Repo M, Lehtinen K, Toivanen P, Granfors K: Antibodies to Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis in ankylosing spondylitis: effect of sulfasalazine treatment. J Rheumatol 1994, 21:2082-2087.
16. Gutierrez-Ureǹa S, Espinoza LR: Methotrexate: the agent of choice for chronic inflammatory disorders: a perspective ten years later. Clin Exp Rheumatol 1995, 13:281-284. An excellent review on the use of methotrexate in chronic inflammatory disorders.
17. Creamers M. C.W, Franssen MJAM, van de Putte LBA, Gribnau FWJ, van Riel PLCM: Methotrexate in severe ankylosing spondylitis: an open study. J Rheumatol 1995, 22:1104-1107. Small open, pilot study demonstrating good response to methotrexate therapy in approximately 40% of AS patients in whom NSAIDs and sulfazalazine had failed.
18. Alberts A, Brighton SW, Kempff P, Werner K, Louw WK, Beek AV, Kiritzinger V, Westerink HP, van Rensburg AJ: Samarium-153-EDTMP for palliation of ankylosing spondylitis, Paget's disease and rheumatoid arthritis. J Nucl Med 1995, 36:1417-1420. Interesting study showing good and long-lasting pain relief in AS patients treated with radiopharmaceutical compound.
19. Oh TH, Brander VA, Hinderer SR, Alpiner N: Rehabilitation in joint and connective tissue disease: 2: inflammatory and degenerative spine diseases. Arch Phys Med Rehabil 1995, 76:S41-S46.
20. Tishler M, Brotovski Y, Yaron M: Effect of spa therapy on patients with ankylosing spondylitis. Clin Rheumatol 1995, 14:21-25. Open study demonstrating significant clinical improvement in AS following treatment with hot mineral baths and mud packs.
21. Viitanen JV, Lehtinen K, Suni J, H Kautiainen: Fifteen months' follow-up of intensive inpatient physiotherapy and exercise in ankylosing spondylitis. Clin Rheumatol 1995, 14:413-419. Good study demonstrating significant clinical improvement following 3 or 4 weeks of intensive inpatient physiotherapy.
22. Hidding A, van der Linden S: Factors related to change in global health after group physical therapy in ankylosing spondylitis. Clin Rheumatol 1995, 14:347-351.
23. Bakker C, Van der Linden S, Van Santen-Hoeufft M, Bolwijn P, Hidding A: Problem elicitation to assess patient priorities in ankylosing spondylitis and fibromyalgia. J Rheumatol 1995, 2:1304-1310.
24. Jamieson AH, Alford CA, Bird HA, Hindmarch I, Wright V: The effect of sleep and nocturnal movement on stiffness, pain, and psychomotor performance in ankylosing spondylitis. Clin Exp Rheumatol 1995, 13:73-78.
25. Kuo SC, Kao HC, Liu CL, Yu WK, Lo WH: Surgical treatment of extensive discovertebral destruction in ankylosing spondylitis: a report of two cases. Chung Hua I Hsueh Tsa Chin (Taipei) 1995, 55:189-194.
26. Halm H, Metz-Stevenhagen P, Schmitt A, Zielke K: Surgical treatment of kyphotic spinal deformities in ankylosing spondylitis using the Harrington compression system: longterm results based on the MOPO scales in the framework of a retrospective questionnaire. Z Orthop Ihre Grenzgeb 1995, 133:141-147. Important study demonstrating the beneficial results of spinal corrective surgery according to the patient's viewpoint.
27. Giadman DD, Farewell VT: The role of HLA antigens as indicators of disease progression in psoriatic arthritis: multivariate relative risk model. Arthritis Rheum 1995, 38:845-850. Very good study suggesting that certain HLA antigens may predispose to or protect from disease progression in PsA patients.
28. Gladman DD, Farewell VT, Nadeau C: Clinical indicators of progression in psoriatic arthritis (PsA): multivariate relative risk model. J Rheumatol 1995, 22:675-679. Excellent study demonstrating that the presence of certain clinical parameters may be indicative of poor prognosis in PsA patients.
29. Husted JA, Gladman DD, Long JA, Farewell VT: A modified version of the health assessment questionnaire (HAQ) for psoriatic arthritis. Clin Exp Rheumatol 1995, 13:439-443. Interesting study using a modified version of the Health Assessment Questionnaire, suggesting that psoriatic skin involvement may not have an impact on daily activity in patients with PsA.
30. Espinoza LR, Cuellar ML: Management of psoriatic arthritis. In Practical Rheumatology. Edited by Klippel JH, Dieppe PA. St Louis: Mosby; 1995:243-248.
31. Abu-Shakra M, Gladman D, Carter Thome J, Long J, Gough J, Farewell VT: Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995, 22:241-245. Retrospective study demonstrating progression of radiographic damage despite methotrexate therapy.
32. Nafradi L, Varga L: Experience with long term low dose methotrexate treatment in rheumatoid arthritis and psoriatic arthritis patients. Orv Hetil 1995, 136:1555-1557.
33. Singh YN, Verma KK, Kumar A, Malaviya AN: Methotrexate in psoriatic arthritis. J Assoc Phys (India) 1994, 42:860-862.
34. Berthelot J-M, Maugars Y, Hamidou M, Chiffoleau A, Barrier J, Grolleau J-Y, Prost A: Pancytopenia and severe cytopenia induced by low-dose methotrexate: eight case reports and a review of one hundred cases from the literature (with twenty-four deaths). Rev Rhum Engl Ed 1995, 7-8:477-486. A most interesting and relevant study demonstrating the development of serious morbidity and mortality secondary to bone marrow toxicity in RA and PsA patients receiving methotrexate.
35. Schnabel A, Gross WL: Severe pneumonitis as a complication of low-dose methotrexate therapy in psoriasis-associated polyarthritis [letter]. Dtsch Med Wochenschr 1995, 120:1223-1225.
36. Leeb BF, Witzmann G, Ogris E, Studnicka-Benke A, Andel I, Schweitzer H, Smolen JS: Folic acid and cyanocobalamin levels in serum and erythrocytes during low-dose methotrexate therapy of rheumatoid arthritis and psoriatic arthritis patients. Clin Exp Rheumatol 1995, 13:459-463. Good study demonstrating the lack of correlation between folic acid level and parameters of disease activity in PsA.
37. Mazzanti G, Coloni L, DeSabbata G, Paladini G: Methotrexate and cyclosporin combined therapy in severe psoriatic arthritis: a pilot study. Acta Derm Venereol Suppl (Stockh) 1994, 186:116-117.
38. Yamamoto T, Kimura K, Katayama I, Nishioka K: Successful treatment of severe arthralgia associated with palmoplantar pustulosis with low-dose oral cyclosporin A. J Dermatol 1995, 22:512-514.
39. Mahrle G, Schulze HJ, Färber L, Weidinger G, Steigleder GK: Low-dose short term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement. J Am Acad Dermatol 1995, 32:78-88. Good study demonstrating the efficacy of low-dose cyclosporine therapy in PsA.
40. Spadaro A, Riccieri V, Sili-Scavalli A, Sensi F, Taccari E, Zoppini A: Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study. Clin Exp Rheumatol 1995, 13:589-593. Open controlled study comparing cyclosporine and methotrexate therapy in PsA. Efficacy was comparable; however, withdrawals from therapy were higher for cyclosporine than for methotrexate.
41. Ferraccioli G, Guerra P, Rizzi V, Bartoli E: Cyclosporin A increases somatomedin C insulin growth factor I levels in chronic rheumatic diseases. J Rheumatol 1995, 22:1060-1064. Cyclosporine was shown to have some correlation with somatomedin C and dehydroepiandrosterone sulfate levels.
42. Brückle W, Dexel T, Grasedyck K, Schattenkirchner M: Treatment of psoriatic arthritis with auranofin and gold sodium thiomalate. Clin Rheumatol 1994, 13:209-216.
43. Mader R, Gladman DD, Long J, Gough J, Farewell VT: Does injectable gold retard radiologic evidence of joint damage in psoriatic arthritis? Clin Invest Med 1995, 18:139-143. Gold therapy does not prevent joint damage in PsA patients with a mean disease duration of 6.5 years.
44. Eibschutz B, Baird SM, Weissman MH, Amox DG, Spellman M, Piacquadio D, Carrerra CJ, Carson DA: Oral 2-chlorodeoxyadenosine in psoriatic arthritis. Arthritis Rheum 1995, 38:1604-1609. Pilot study in a small number of patients showing improvement in both skin and joint involvement with this biologic agent.
45. Jullien D, Wolkenstein P, Roupie E, Roujeau JC, Revuz J: Toxic epidermal necrolysis after sulfasalazine treatment of mild psoriatic arthritis: warning on the use of sulfasalazine for a new indication. Arthritis Rheum 1995, 38:573.
46. Veale DJ, Morley KD: Sulphasalazine-induced lupus in psoriatic arthritis. Br J Rheumatol 1995, 34:383-384.
47. Hammoudeh M, Slam R, Khanjar I: Spondylitis-like and symmetric polyarthralgia associated with gemfibrozil therapy. Br J Rheumatol 1995, 34:692.
48. Hernàndez Rodriquez I, Allegue F: Achilles and suprapatellar tendinitis due to isotretinoin. J Rheumatol 1995, 22:2009-2010.
49. Brophy DP, Cunnane G, Fitzgerald O, Gibney RG: Ultrasound guidance for injection of soft tissue lesions around the heel in chronic inflammatory arthritis [technical report]. Clin Radiol 1995, 50:120-122.
50. SH Soulkiasian, Foster S, Raizman MB: Treatment strategies for scleritis and uveitis associated with inflammatory bowel disease. Am J Ophthalmol 1994, 118:601-611.
51. Lauhio A, Konttinen YT, Tschesche H, Nordström D, Salo T, Lahdevihta J, Golub LM, Sarsa T: Reduction of matrix metalloproteinase 8-neutrophil collagenase levels during long-term doxycycllne treatment of reactive arthritis. Antimicrobial Agents Chemother 1994, 38:400-402.
52. Lauhio A, Salo T, Ding Y, Konttinen YT, Nordstrom D, Tschesche H, Lahdevirta J, Golub LM, Sorsa T: In vivo inhibition of human neutrophil collagenase (MMP-8) activity during long-term combination therapy of doxycycline and non-steroidal anti-inflammatory drugs (NSAID) in acute reactive arthritis. Clin Exp Immunol 1994, 98:21-28.